Revive Rx LLC dba Revive Rx Pharmacy

Has Revive Rx LLC dba Revive Rx Pharmacy received an FDA warning letter about GLP-1 drugs?

No FDA warning letter to Revive Rx LLC dba Revive Rx Pharmacy naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 2 drug recall reports for it naming tirzepatide, the latest initiated Apr 20, 2024.

FDA records in this index name Revive Rx LLC dba Revive Rx Pharmacy from May 11, 2023 to Apr 20, 2024.

Type named in FDA records
Not stated
FDA warning letters
0
Drug recall reports
2
Drugs named
Tirzepatide
Latest record
Apr 20, 2024

FDA warning letters

No FDA warning letters in this index.

Drug recalls

Record
Apr 20, 2024Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77...Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionateClass IOngoingD-0511-2024
May 11, 2023Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, N...Sub-potent DrugClass IIOngoingD-0771-2023

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Revive RX LLC, dba Revive RX Pharmacy, Houston, TX (503A)

7 listed actions, including 4 Form 483s, 1 warning letter and 1 untitled letter (2021 to 2026).

Document
Mar 27, 2026Form 483483 Issued 3/27/2026fda.gov
Sep 22, 2025Warning letterWarning Letter Issued 09/22/2025fda.gov
Feb 7, 2025Form 483483 Issued 02/07/2025fda.gov
Jan 22, 2025FMD-145 letterFMD-145 Letter Issued 01/22/2025Not linked by FDA
Jun 30, 2023Untitled letterUntitled Letter Issued 06/30/2023FDA copy (archived)
May 4, 2022Form 483483 Issued 05/04/2022FDA copy (archived)
Aug 6, 2021Form 483483 Issued 08/06/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Revive RX Pharmacy (Revive RX LLC), Houston, TX.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.